DATE: _//-/8-0.2	APPL. S.N.: 071623,709
TO EXAMINER: M. Berch	ART UNIT: _/624
MOSE MONTGOMERY ROOM [1 E /8	MAILROOM DATE 1/-8-02
AFTER FINAL YES	
The T.D. is PROPER and has been recorded. (See 14.23).	
[] The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below. (See 14.24).	
[] The recording fee of \$ has not been submitted nor is there any pre authorization in the application file to charge to a deposit account. (See 14.26.07)	
[] Application Examiner has not processed T.D. fee. (See fee authorization).	
[] The T.D. does not satisfy Rule 321(b)(3) in that the person who has signed the T.D. has not stated his/her interest (and/or the extent of the interest of the business entity represented by the signature) in the application/patent. (See 14.26 and 14.26.01).	
[] The T.D. lacks the enforceable only during the common owership clause needed to overcome a double patenting rejection, Rule 321(c). (See 14.27, 14.27.01).	
[] It is directed to a particular claims(s), which is not acceptable since "the disclaimer must be of a terminal portion of the term of the entire patent to be granted". MPEP 1490. (See 14.26, 14.26.02).	
 The person who signed the terminal disclaimer: has failed to state his/her capacity to sign for the business entity, (See 14.28). is not recognized as an officer of the assignee, (See 14.29 and possibly 14.29.01). 	
[] No documentary evidence of a chain of title from the original inventor(s) to assignee has been submitted, nor is the reel and frame specified as to where such evidence is recorded in the office. 37 CFR 3.73(b). (See 1140 O.G. 72). <u>NOTE</u> : This documentary evidence or the specifying of the reel and frame may be found in the T.D. <u>or</u> in a seperate paper <u>submitted by applicant</u> . (See 14.30).	
[] No "statement" specifying that the evidentiary documents have been reviewed and that, to the best of the assignee's knowledge and belief the title is in the assignee seeking to take action. 37 CFR 3.73(b). (See 1140 O.G. 72) (See 14.31).	
[] The T.D. is not signed. (See 14.26, 14.26.3). or 14.26.03 if TD is not signed by all the owners.	
[] Attorney not of record in oath/decl. or a seperate paper filed appointing a new or associate attorney. (See 14.29.01).	
[] The serial number of the application (or the number of the patent) which forms the basis for the double patenting is missing or incorrect. (See 14.32).	
[] The serial number of this application (or the number of the patent in reexam or reissue case(s) being disclaimed is missing or incorrect. (See 14.26, 14.26.04 or 14.26.05).	
[] The period disclaimed is incorrect or not specified. (See 14.27, 14.27.2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)	
[] Other:	
[] Suggestion to request refund of \$ (See 14.35, 14.36).	
[] EXAMINER NOTE: IF APPLICATION IS IN CONDITION FOR ALLOWANCE ANY OF THE ABOVE INFORMALTIES MAY BE FAXED IN TO THE GROUP	
FOR SAMPLE TERMINAL DISCLAIMERS AND CERTIFICATES:	
 Sample of a TD over a pending application and assignee Certificate (See 14.37). Sample of a TD over a prior patent and assignee Certificate (See 14.38). Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39) 	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BJORE et al

Atty. Ref.: 3525-96

Serial No. 09/623,709

Group: 1624

Filed: September 7, 2000

Examiner: Berch, Mark L.

For: NEW BISPIDINE COMPOUNDS USEFUL IN

THE TREATMENT OF CARDIAC

ARRYTHMIAS

RECEIV

NOV 1 3 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents Washington, DC 20231

TERMINAL DISCLAIMER

Sir:

Your petitioner, AstraZeneca AB, having a business address at S-151 85, Södertälje, Sweden, the undersigned being the attorney of record, represents that it is the assignee, as evidenced by recordal on September 7, 2000 of an assignment from the inventors at Reel 012144, Frame 0073, of all right, title and interest in and to application Serial No. 09/623,709, filed September 7, 2000 for NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRYTHMIAS. Your petitioner hereby disclaims the terminal part of any patent granted on the aboveidentified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from application Serial No. 09/623,705, and hereby agrees that any patent so granted on the

11/12/2002 TLUU11 00000054 09623709

01 FC:1814

682284

above-identified application shall be enforceable only for and during such period that the legal title to such patent granted on the above-identified application shall be the same as the legal title to any patent issuing from application Serial No. 09/623,705, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from application Serial No. 09/623,705 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The evidentiary documents accompanying this document or referred to above have been reviewed by the undersigned and it is certified that to the best of the assignee's knowledge and belief, title is in the assignee seeking to take action.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

Name: Leonard C. Mitchard

Reg. No. 29,009

Date of Execution